HBIO Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane

03
Prezzo $8.34
Capitalizzazione di Mercato (MRQ) $38M
P/E (TTM) -5.6
EPS (TTM) $-1.50
Ricavi (TTM) $88M
ROE (TTM) -89.9%
D/E Debito/Patrimonio (MRQ) 4.9
Intervallo 52 sett. $0–$8

HBIO Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione

04
intervallo
barre

La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.

Split azionari 2
Data ex-dividendo Split Tipo
16 Marzo 2026 1-for-10 Inverso
04 Novembre 2013 1319-for-1000 Avanti

Informazioni su Harvard Bioscience, Inc. - Common Stock Panoramica della società da Wikipedia

05 · wikidata

Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.

Headquartered in Holliston, Massachusetts, United States, the company's brands include: Biochrom, BTX, CMA, Data Sciences International (DSI), Harvard Apparatus, HEKA, Hugo Sachs Elektronik, KD Scientific, Multi Channel Systems (MCS), Panlab, and Warner Instruments. The company has approximately 355 employees, with 216 of those in the USA, and its principal manufacturing facilities are in New Brighton, Minnesota, Holliston, Massachusetts, Reutlingen, Germany, Barcelona, Spain, and March, Germany.

History

Harvard Bioscience was founded in 1901 by Dr. William T. Porter of Harvard Medical School. He began manufacturing his own physiology teaching equipment in the basement of the Harvard Medical School. Dr. Porter went on to found the American Journal of Physiology and became one of the leading physiologists of his day.

The company invented the mechanical syringe pump in the 1950s and a computer-controlled dosing pump in the 1980s.

In the early 1980s, the company started using the name Harvard Bioscience; the name was not officially changed to Harvard Bioscience, Inc. until 2000. The company completed their initial public offering on December 7, 2000. The names Harvard Apparatus and Harvard Bioscience are used pursuant to a license agreement between Harvard University and Harvard Bioscience, Inc.

From 1996 to 2005 the company completed 17 business acquisitions, including the BTX division acquisition in 2003.

In 2007 the company sold most of its Capital Equipment Business, including its Genomic Solutions division and its Belgian subsidiary, Maia Scientific.

The company spun off Harvard Apparatus Regenerative Technology, Inc. (HART) in 2013 and Jeff Duchemin became CEO in August 2013.

In 2014 the company acquired Multi Channel Systems MCS GmbH (MCS) and Triangle BioSystems, Inc. (TBSI).

In 2015 the company acquired HEKA Electronik of Germany.

In 2016 the company divested AHN Biotechnologie GmbH, which it acquired in 2012.

In 2018 Harvard Bioscience acquired St. Paul, Minnesota-based Data Sciences International for $71 million and sold its Denville Scientific subsidiary to Thomas Scientific for $20 million.

James Green was named President and CEO in July 2019 and the company's performance declined during the latter half of his six-year tenure. In 2019, the company's gross revenue was $116 million, down from $120.7 million in 2018. The company ended the year with $55 million in loans, down from $62.4 million in loans at the end of 2018. Loans were through Cerberus Capital and were subsequently refinanced in 2020 with a syndicate led by Citizens Financial Group. In September 2019 the company announced a restructuring program, including closing their Connecticut operation, downsizing in the United Kingdom, and a reduction in force of over 10% of headcount. Several additional restructurings were implemented from 2020 to 2024.

For approximately nine months in 2019-2020 the company had an activist investor in its stock, Engine Capital.

In 2020, during the COVID-19 pandemic, Harvard Bioscience received $6.1 million in federally backed small business loans from PNC Bank as part of the Paycheck Protection Program. The company promptly repaid this loan after receiving scrutiny related to it.

In the of summer of 2025 the board of directors of Harvard Bioscience was reconstituted and a new CEO was appointed and in December 2025 the company successfully refinanced its debt, obtaining a $40 million credit facility with BroadOak Capital.

Products

Harvard Bioscience offers a wide array of products for life science research. Their product portfolio is broken into five market segments: Fluidics, Laboratory Equipment & Supplies, Molecular Analysis, Cell Analysis, and Physiology.

Finance

The revenue of the company grew from $11.5 million in 1997 to $108.2 million in 2010, a CAGR of 19%. The revenue of the company for fy 2013 reached 105.57 million with the profit margin of 0.12% and operation margin of -1.01%.

In the 25 years since Harvard Bioscience went public in 2000, there have been several intervals in which the company's value was grossly misunderstood by the market and its stock significantly undervalued, including, most recently, in 2019 and 2026.

Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗

Wikidata ↗

settoreHealthcare industriaLife Sciences Tools & Services dipendenti316 paeseUS

Performance decennale Andamento di ricavi, utile netto, margini e EPS

06
Ricavi$87M
2016-12-31 → 2025-12-31
EPS$-1.28
2016-12-31 → 2025-12-31
Flusso di cassa libero$5M
2018-12-31 → 2025-12-31
Margine netto-11.9%
2016-12-31 → 2025-12-31
Valutazione e Rapporti 07–12

Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?

Metrica Tendenza 5 anni HBIO media 5 anni Mediana dei peer Verdetto
P/E (TTM) -5.6media 5 anni ≈-21.7 ≈-21.7 · ·
P/S (TTM) 0.4media 5 anni ≈1.4 ≈1.4 · ·
P/B (MRQ) 5.1media 5 anni ≈2.4 ≈2.4 · ·
EV / EBITDA -1.3media 5 anni ≈51.1 ≈51.1 · ·
Prezzo / FCF (TTM) -33.9media 5 anni ≈802.1 ≈802.1 · ·
Prezzo / Flusso di cassa (TTM) 58.3media 5 anni ≈83.3 ≈83.3 · ·
EV / Revenue (EV / Ricavi) 0.7media 5 anni ≈1.7 ≈1.7 · ·
EV / FCF 11.8media 5 anni ≈900.4 ≈900.4 · ·
Prezzo / Valore contabile tangibile (MRQ) 31.7 · · ·

La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.

valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana

Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili

14
Sorpresa media -18.3%
Prossimo report Nov 04, 2026
PeriodoRapportoEPS ActualEPS StimatoSorpresa
30 Giugno 2026 Ago 11, 2026 $-0.14 $-0.21 34.6%
31 Marzo 2026 Mag 12, 2026 $-0.77 $-0.63 -21.8%
31 Dicembre 2025 $0.00 $0.36 -100.0%
30 Settembre 2025 $0.00 $0.05 -100.0%
30 Giugno 2025 $-0.10 $-0.10 2.0%
31 Marzo 2025 $-0.10 $-0.41 75.5%

Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario

15
Conto Economico 17
Metrica Tendenza 202520242023202220212020201920182017201620152014
Revenue $87M$94M$112M$113M$119M$102M$116M$121M$77M$105M$109M$109M
Cost of Revenue $37M$39M$46M$53M$51M$44M$52M$58M$38M$56M$60M$59M
Gross Profit $50M$55M$66M$61M$68M$58M$64M$63M$39M$48M$49M$49M
R&D Expense $9M$10M$12M$12M$11M$9M$11M$11M$6M$5M$6M$5M
SG&A Expense $18M$21M$23M$24M$24M$24M$23M$21M$18M$21M$20M$17M
Operating Expenses $98M$61M$64M$68M$66M$58M$64M$62M$40M$51M$50M$43M
Operating Income $-49M$-6M$2M$-7M$2M$221.0K$377.0K$984.0K$-635.0K$-3M$-2M$7M
Interest Expense ·······$5M$713.0K$639.0K$846.0K$990.0K
Other Non-op $-3M$-325.0K$-227.0K$302.0K$-666.0K$-806.0K$-469.0K$-4M$-739.0K$-179.0K$-1M$-1M
Pretax Income $-57M$-12M$-3M$-9M$-140.0K$-7M$-6M$-8M$-3M$-3M$-4M$4M
Income Tax $-686.0K$740.0K$859.0K$337.0K$148.0K$518.0K$-815.0K$-4M$-605.0K$1M$15M$2M
Net Income $-57M$-12M$-3M$-10M$-288.0K$-8M$-5M$-3M$-865.0K$-4M$-19M$2M
EPS (Basic) $-1.28$-0.28$-0.08$-0.23$-0.01·$-0.12$-0.08$-0.02$-0.13$-0.57$0.07
EPS (Diluted) $-1.28$-0.28$-0.08$-0.23··$-0.12$-0.08$-0.02$-0.13$-0.57$0.07
Shares (Basic) 44,391,00043,538,00042,420,00041,413,00040,343,00038,640,00037,813,58036,453,12634,753,32534,211,52133,592,77532,170,683
Shares (Diluted) 44,391,00043,538,00042,420,00041,413,00040,343,00038,640,00037,813,58036,453,12634,753,32534,211,52133,592,77533,236,569
EBITDA $-49M$-6M$2M$-7M$2M$221.0K$377.0K$984.0K$-101.0K$-3M$-2M·
Stato Patrimoniale 28
Metrica Tendenza 202520242023202220212020201920182017201620152014
Cash & Equivalents $9M$4M$4M$5M$8M$8M$8M$8M$6M$6M$7M$14M
Receivables $16M$15M$16M$17M$22M$18M$21M$21M$13M$16M$18M$16M
Inventory $21M$23M$25M$26M$28M$22M$22M$25M$17M$20M$22M$21M
Other Current Assets $3M$3M$4M$3M$4M$3M$2M$3M$4M$4M$4M$5M
Current Assets $48M$45M$49M$51M$62M$52M$54M$58M$48M$45M$51M$57M
PP&E (Net) $5M$5M$4M$3M$3M$4M$5M$6M$4M$4M$6M$5M
PP&E (Gross) $23M$21M$18M$18M$18M$21M$20M$23M$19M$19M$22M$20M
Accum. Depreciation $18M$16M$14M$15M$14M$17M$15M$17M$16M$15M$16M$15M
Goodwill $10M$56M$57M$56M$58M$59M$57M$57M$36M$38M$40M$40M
Intangibles $8M$11M$16M$21M$27M$33M$38M$46M$10M$17M$21M$21M
Other Non-current Assets $3M$3M$6M$8M$5M$1M$2M$2M$324.0K$128.0K$152.0K$380.0K
Total Assets $80M$127M$137M$145M$162M$156M$165M$169M$109M$108M$120M$136M
Accounts Payable $4M$5M$6M$6M$5M$6M$5M$7M$4M$6M$9M$6M
Accrued Liabilities ······$6M$7M$4M$5M$4M$4M
Current Liabilities $22M$55M$27M$23M$25M$21M$25M$25M$14M$15M$19M$18M
Capital Leases $7M$6M$5M$5M$6M$7M$8M·····
Deferred Tax $317.0K$710.0K$776.0K$590.0K$2M$2M$2M$2M$3M$6M$4M$1M
Other Non-current Liabilities $1M$1M$1M$1M$486.0K$3M$749.0K$3M····
Total Liabilities $66M$63M$64M$73M$79M$80M$83M$86M$28M$36M$42M$40M
Long-term Debt $36M$37M$37M$47M$48M$48M$54M$61M$12M$14M$19M$21M
Total Debt $36M$37M$37M$47M$49M$48M$50M$59M$9M$11M$16M·
Common Stock $447.0K$441.0K$434.0K$454.0K$452.0K$444.0K$438.0K$436.0K$419.0K$418.0K$416.0K$397.0K
Retained Earnings $-215M$-158M$-146M$-142M$-133M$-132M$-125M$-120M$-117M$-116M$-112M$-93M
Treasury Stock ····$0$11M······
AOCI $-12M$-16M$-14M$-15M$-10M$-13M$-13M$-14M$-11M$-17M$-12M$-8M
Stockholders' Equity $14M$63M$73M$72M$83M$77M$82M$83M$81M$72M$78M$95M
Liabilities + Equity $80M$127M$137M$145M$162M$156M$165M$169M$109M$108M$120M$136M
Shares Outstanding 4,471,98944,074,47543,394,50942,081,70741,142,87639,407,08038,188,20837,378,80235,018,47835,018,47833,979,26532,563,256
Flusso di cassa 16
Metrica Tendenza 202520242023202220212020201920182017201620152014
Stock-based Comp $2M$4M$5M$4M$4M$4M$3M$3M$4M$3M$3M$2M
Deferred Tax $-553.0K$310.0K$228.0K$-498.0K$-371.0K$-143.0K$-398.0K$-4M$-2M$-279.0K$15M$1M
Amort. of Intangibles $4M$5M$6M$6M$6M$6M$6M$5M$2M$3M$3M$3M
Restructuring $200.0K$800.0K$391.0K$2M$1M$2M$1M·$0$-4.0K$788.0K$1M
Operating Cash Flow $7M$1M$14M$1M$1M$9M$8M$3M$1M$5M$705.0K$4M
CapEx $1M$3M$2M$2M$1M$1M$1M$986.0K$890.0K···
Investing Cash Flow $-2M$-1M$-2M$-2M$-1M$-1M$-229.0K$-54M$-917.0K$-62.0K$-8M$-14M
Debt Issued $40M$0··········
Net Debt Issued $15M$-6M$-4M$-3M$-4M$-67M$-12M$-20M$-5M$-9M$-8M·
Stock Issued ·······$5M$160.0K$182.0K$2M$2M
Net Stock Activity ·······$5M$160.0K$182.0K$2M·
Financing Cash Flow $-1M$-131.0K$-12M$-3M$-252.0K$-8M$-8M$53M$-2M$-5M$-540.0K$-1M
Net Change in Cash $5M$-175.0K$-225.0K$-3M$-496.0K$-18.0K$162.0K$2M$137.0K$-1M$-7M$-12M
Taxes Paid $-98.0K$-159.0K$207.0K$534.0K$577.0K$416.0K$374.0K$98.0K$13.0K···
Free Cash Flow $5M$-1M$12M$-438.0K$67.0K$8M$7M$2M····
Levered FCF ·······$-995.1K····
Redditività 8
Metrica Tendenza 202520242023202220212020201920182017201620152014
Gross Margin 57.7%58.2%58.9%53.7%56.9%56.9%55.4%52.3%46.7%46.3%44.8%·
Operating Margin -56.1%-6.6%1.7%-6.1%1.7%0.22%0.32%0.81%-0.10%-2.9%-1.6%·
Net Margin -65.5%-13.2%-3.0%-8.4%-0.24%-7.6%-4.0%-2.4%-0.85%-4.1%-17.5%·
Pretax Margin -66.3%-12.4%-2.3%-8.1%-0.12%-7.1%-4.7%-6.6%-2.1%-2.9%-3.3%·
EBITDA Margin -56.1%-6.6%1.7%-6.1%1.7%0.22%0.32%0.81%-0.10%-2.9%-1.6%·
ROA -54.9%-9.4%-2.4%-6.2%-0.18%-4.9%-2.8%-2.1%-0.80%-3.8%-14.9%·
ROE -384.8%-19.3%-4.6%-13.2%-0.36%-10.2%-5.9%-3.6%-1.1%-5.8%-22.0%·
ROIC -96.8%-6.6%2.3%-6.0%3.2%0.19%0.24%0.37%-0.05%-5.0%-9.6%·
Liquidità e Solvibilità 5
Metrica Tendenza 202520242023202220212020201920182017201620152014
Current Ratio 2.20.81.82.22.42.52.12.73.43.12.6·
Quick Ratio 1.10.30.80.91.21.21.11.41.61.51.3·
Debt / Equity 2.60.60.50.70.60.60.60.70.10.20.2·
LT Debt / Equity 2.60.00.40.60.50.60.60.70.10.20.2·
Interest Coverage ·······0.2-0.1-4.7-2.0·
Efficienza 3
Metrica Tendenza 202520242023202220212020201920182017201620152014
Asset Turnover 0.80.70.80.70.70.60.70.90.90.90.8·
Inventory Turnover 1.71.61.81.92.12.02.22.72.62.72.8·
Receivables Turnover 5.66.16.85.96.05.35.56.96.46.36.5·
Per Azione 5
Metrica Tendenza 202520242023202220212020201920182017201620152014
Book Value / Share $0.31$1.44$1.68$1.72$2.03$1.95$2.14$2.21$2.31$2.10$2.28·
Revenue / Share $1.95$2.16$2.65$2.74$2.95$2.64$3.07$3.31$2.93$3.06$3.23·
Cash Flow / Share $0.15$0.03$0.33$0.03$0.03$0.24$0.21$0.08$0.03$0.16$0.02·
Cash / Share $0.19$0.09$0.10$0.11$0.19$0.21$0.22$0.22$0.16$0.16$0.20·
EPS (TTM) $-1.28$-0.28$-0.08$-0.23·$-0.21$-0.12$-0.08$-0.02$-0.13$-0.57$0.07
Tassi di Crescita 3
Metrica Tendenza 202520242023202220212020201920182017201620152014
Revenue YoY -8.1%-16.1%-0.96%-4.7%16.5%·······
Revenue CAGR 3Y -8.6%-7.5%3.2%·········
Revenue CAGR 5Y -3.2%···········
Valutazione (TTM) 13
Metrica Tendenza 202520242023202220212020201920182017201620152014
Revenue TTM $87M$94M$112M$113M$119M$102M$116M$121M$77M$105M$109M$109M
Net Income TTM $-57M$-12M$-3M$-10M$-288.0K$-8M$-5M$-3M$-865.0K$-4M$-19M$2M
Market Cap $30M$93M$232M$117M$290M$169M$116M$119M$116M$105M$118M·
Enterprise Value $57M$126M$265M$159M$331M$209M$158M$169M$119M$111M$128M·
P/E -0.5-7.5-66.9-12.0·-20.4-25.4-39.8-165.0-23.5-6.181.0
P/S 0.31.02.11.02.41.71.01.01.51.01.1·
P/B 2.21.53.21.63.52.21.41.41.41.51.5·
P / Cash Flow 4.564.616.5101.2229.818.114.541.2109.319.5167.2·
P / FCF 5.5-77.219.0-266.14329.220.717.162.6····
EV / EBITDA -1.2-20.3139.8-23.0160.1945.8419.8172.2-1176.3-37.0-74.5·
EV / FCF 10.5-104.821.6-363.44938.025.623.289.3····
EV / Revenue 0.71.32.41.42.82.01.41.41.51.11.2·
Earnings Yield -191.0%-13.3%-1.5%-8.3%·-4.9%-3.9%-2.5%-0.61%-4.3%-16.4%1.2%

Periodo più recente a sinistra · valori nulli mostrati come ·

Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni

16
Metrica 2025-12-312024-12-312023-12-312022-12-312021-12-31
Ricavi $87M $94M $112M $113M $119M
Margine Lordo % 57.7% 58.2% 58.9% 53.7% 56.9%
Margine Operativo % -56.1% -6.6% 1.7% -6.1% 1.7%
Utile netto $-57M $-12M $-3M $-10M $-288.0K
EPS Diluito $-1.28 $-0.28 $-0.08 $-0.23 ·

Proprietari istituzionali (13F) 8 filer · $5.7M totale · Aggiornato al 30 Giugno 2026

17

Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.

Detentori 8
Valore detenuto $5.7M
Nuove posizioni 0
Posizioni chiuse 0
Attività istituzionale — Q2 2026 vs trimestre precedente
Nuove posizioni Posizioni chiuse Aumentato Diminuito Variazione netta delle azioni
0 (0 vs trimestre precedente) 0 (-57 vs trimestre precedente) 2 (+2 vs trimestre precedente) 0 (-3 vs trimestre precedente) +90K

Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.

Istituzione Valore Azioni % di 13F tracciati Tipo
AMH Equity Ltd $1.774.844 4.047.535 31,32% Azioni
VANGUARD GROUP INC $1.286.671 1.923.275 22,71% Azioni
Meros Investment Management, LP $1.125.401 182.992 19,86% Azioni
NANO CAP NEW MILLENNIUM GROWTH FUND L P $879.954 143.082 15,53% Azioni
TWO SIGMA ADVISERS, LP $587.578 878.556 10,37% Azioni
Point72 Asia (Singapore) Pte. Ltd. $6.445 14.697 0,11% Azioni
WOLVERINE TRADING, LLC $5.102 11.600 0,09% Opzione Call
Financial Connections Group, Inc. $0 30 0,00% Azioni

Attivisti e proprietari del 5%+ 5 partecipazioni

18

Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.

Depositante Depositato Partecipazione Stato Scopo Deposito
BroadOak Income Fund, L.P., BroadOak Fund VI, L.P., BroadOak Capital Partners, LLC, William Snider 23 Marzo 2026 15,97% Deposito iniziale · SEC
ENGINE CAPITAL, L.P., ENGINE JET CAPITAL, L.P., ENGINE CAPITAL MANAGEMENT, LP, ENGINE CAPITAL MANAGEMENT GP, LLC, ENGINE INVESTMENTS, LLC, ARNAUD AJDLER ×5 depositi 22 Giugno 2020 · Deposito iniziale · SEC
HSO Limited Partnership Skystone Advisors LLC Kerry Nelson ×2 depositi 20 Maggio 2008 · Deposito iniziale · SEC
14 Dicembre 2007 · Deposito iniziale · SEC
Persona segnalante non divulgata 29 Luglio 2002 · Deposito iniziale M&A / vendita SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Insider aziendali 34 insider · 14 dirigenti · 18 direttori

19
Insider Ruolo Ultima attività Azioni possedute Acquisti 12m Vendite 12m Netto 12m
John D Duke Chief Executive Officer 20 Marzo 2026 A 180.000 1 0 $25.050
Jeffrey Duchemin Chief Executive Officer 07 Luglio 2019 D 464.528 0 0 $0
Mark T Frost Chief Financial Officer 20 Marzo 2026 A 47.500 1 0 $25.000
Jennifer Cote Chief Financial Officer 19 Marzo 2025 F 159.019 0 0 $0
Michael A. Rossi Chief Financial Officer 29 Dicembre 2022 F 260.540 0 0 $0
Kamalam Unninayar Chief Financial Officer 07 Marzo 2019 A 73.858 0 0 $0
Bryce Anthony Chicoyne Chief Financial Officer 01 Maggio 2007 A · 0 0 $0
Mark A Norige President, Harvard Apparatus 01 Maggio 2007 A · 0 0 $0
David L Strack President of Subsidiary 25 Maggio 2005 A · 0 0 $0
Kenneth Fletcher Olson Chief Operating Officer 29 Dicembre 2021 F 155.595 0 0 $0
Yash Singh Executive Vice President 31 Ottobre 2019 A 39.286 0 0 $0
Yong Sun VP - Commercial Operations 01 Gennaio 2019 F 242.805 0 0 $0
Yoav Sibony VP - Global Sales 03 Agosto 2015 A 21.582 0 0 $0
Paul Bailey VP, Finance & Admin. 25 Maggio 2005 A · 0 0 $0
Seth Benjamin Benson Direttore 09 Giugno 2026 A 27.556 0 0 $0
Katherine A. Eade Direttore 09 Giugno 2026 A 58.669 0 0 $0
Robert E. Gagnon Direttore 09 Giugno 2026 A 27.556 0 0 $0
William Snider Direttore 09 Giugno 2026 A 48.556 2 0 $103.604
Stephen J Denelsky Direttore 09 Giugno 2026 A 37.556 1 0 $48.700
James W Green Direttore 15 Agosto 2025 D 2.452.566 0 0 $0
Thomas W Loewald Direttore 21 Maggio 2024 A 295.311 0 0 $0
Bertrand Loy Direttore 21 Maggio 2024 A 56.575 0 0 $0
Alan I Edrick Direttore 21 Maggio 2024 A 273.911 0 0 $0
John F Kennedy Direttore 23 Marzo 2021 G 323.344 0 0 $0
Susan M. Steele Direttore 04 Gennaio 2021 A 49.400 0 0 $0
George Uveges Direttore 12 Marzo 2018 M 142.685 0 0 $0
Earl R Lewis Direttore 02 Gennaio 2018 A 477.050 0 0 $0
David Green Direttore 07 Febbraio 2017 S 925.571 0 0 $0
Neal J Harte Direttore 25 Maggio 2016 M 106.399 0 0 $0
Robert A Dishman Direttore 28 Aprile 2015 A 51.055 0 0 $0
Chane Graziano Proprietario del 10% 07 Novembre 2013 G 3.005.150 0 0 $0
HSO LIMITED PARTNERSHIP Proprietario del 10% 16 Maggio 2008 S 2.757.257 0 0 $0
Thomas Mcnaughton · 01 Novembre 2013 J 171.613 0 0 $0
Susan M Luscinski · 01 Novembre 2013 J 469.720 0 0 $0

Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato

Proprietà ETF Posseduti da 2 ETF

20

Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.

Fondo Peso Unità Aggiornato al Fonte
VXF · VANGUARD INDEX FUNDS 0,00% 42.043 SH 19 Agosto 2026 Giornaliero
VTI · VANGUARD INDEX FUNDS 0,00% 123.470 SH 19 Agosto 2026 Giornaliero

HBIO Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo

21
rating · 8 analisti COMPRA
Target mediano $7.50 -10,1%
2 25,0% Acquisto forte
4 50,0% Compra
2 25,0% Mantieni
0 0,0% Vendi
0 0,0% Vendita forte

Target Price a 12 Mesi

1 analisti · 2026-09-20

Target medio $7.50 -10,1%

Basso$7.50 Media$7.50 Alto$7.50

Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore

22

Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.

Ticker Capitalizzazione di Mercato P/E Rev YoY Margine Netto ROE Margine lordo
HBIO $30M -0.5 -8.1% -65.5% -384.8% 57.7%
HYFT · · · -89.7% -78.9% 58.8%
CIRC · · · · · ·
RPID · -2.8 19.7% -140.3% -107.4% ·
BNGO $16M -0.3 -7.4% -92.6% -58.8% ·
TMO $257.86B 32.7 3.9% 15.0% 13.0% ·

Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi

26

Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.

La tua selezione è salvata e ti segue su tutti i ticker.

Fonte: SEC 10-Q depositato Ago 11, 2026